Clarivate Stock Slumps Following $600 Million Divestiture

Investors sent Clarivate shares tumbling 4.8% to $2.47 on Monday following the company’s announcement that it will offload its life-science and healthcare division to New York investment firm Altaris. The transaction, valued at $600 million, marks a sharp pivot in the London-based data provider’s long-term strategy.

July 6, 2026, 06:40 PM 635 0

The sale leaves the company’s stock down more than 26% since the beginning of the year, reflecting sustained downward pressure on its market valuation. Management intends to use the capital to sharpen its focus on AI-driven analytics, specifically targeting its intellectual property, academic, and government services sectors.

Clarivate expects the deal to close by the end of the calendar year, pending final regulatory clearances. By shedding the healthcare segment, the firm aims to streamline its portfolio and prioritize high-growth software and intelligence solutions.

When reusing this material a link to Money Talk is required.